These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 35032878)

  • 1. Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies.
    Ozakbas S; Baba C; Dogan Y; Cevik S; Ozcelik S; Kaya E
    Mult Scler Relat Disord; 2022 Feb; 58():103486. PubMed ID: 35032878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity-Does it matter?
    Tütüncü M; Demir S; Arslan G; Dinç Ö; Şen S; Gündüz T; Uzunköprü C; Gümüş H; Tütüncü M; Akçin R; Özakbaş S; Köseoğlu M; Bünül SD; Gezen O; Tezer DÇ; Baba C; Özen PA; Koç R; Elverdi T; Uygunoğlu U; Kürtüncü M; Beckmann Y; Doğan İG; Turan ÖF; Boz C; Terzi M; Tuncer A; Saip S; Karabudak R; Kocazeybek B; Efendi H; Bilge U; Siva A
    Mult Scler Relat Disord; 2023 Jul; 75():104761. PubMed ID: 37247488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
    Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
    Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab.
    Altieri M; Capuano R; Conte M; Donnarumma G; Grimaldi E; Coppola N; Galdiero M; d'Ambrosio A; Tedeschi G; Gallo A
    Neurol Sci; 2022 May; 43(5):2947-2949. PubMed ID: 35171373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
    Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
    Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients.
    Erol Ç; Yanık Yalçın T; Sarı N; Bayraktar N; Ayvazoğlu Soy E; Yavuz Çolak M; Azap Ö; Arslan H; Haberal M
    Exp Clin Transplant; 2021 Dec; 19(12):1334-1340. PubMed ID: 34951350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
    Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A;
    Front Immunol; 2022; 13():868915. PubMed ID: 35432335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects.
    Maniscalco GT; Manzo V; Ferrara AL; Perrella A; Di Battista M; Salvatore S; Graziano D; Viola A; Amato G; Moreggia O; Di Giulio Cesare D; Barbato S; Servillo G; Longo K; Di Giovanni M; Scarpati B; Muggianu SM; Longo G; Russo G; Andreone V; De Rosa V
    Mult Scler Relat Disord; 2022 Feb; 58():103455. PubMed ID: 34929455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.
    Sormani MP; Inglese M; Schiavetti I; Carmisciano L; Laroni A; Lapucci C; Da Rin G; Serrati C; Gandoglia I; Tassinari T; Perego G; Brichetto G; Gazzola P; Mannironi A; Stromillo ML; Cordioli C; Landi D; Clerico M; Signoriello E; Frau J; Ferrò MT; Di Sapio A; Pasquali L; Ulivelli M; Marinelli F; Callari G; Iodice R; Liberatore G; Caleri F; Repice AM; Cordera S; Battaglia MA; Salvetti M; Franciotta D; Uccelli A;
    EBioMedicine; 2021 Oct; 72():103581. PubMed ID: 34563483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis.
    Pellicano C; Campagna R; Oliva A; Leodori G; Miglionico M; Colalillo A; Mezzaroma I; Mastroianni CM; Turriziani O; Rosato E
    Clin Rheumatol; 2022 Sep; 41(9):2755-2763. PubMed ID: 35614287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher antibody responses after mRNA-based vaccine compared to inactivated vaccine against SARS-CoV-2 in Behcet's syndrome.
    Ozdede A; Nohut OK; Atli Z; Tok YT; Guner S; Yilmaz E; Ucar D; Uygunoglu U; Hamuryudan V; Seyahi E
    Rheumatol Int; 2022 Oct; 42(10):1741-1750. PubMed ID: 35779083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.
    Pitzalis M; Idda ML; Lodde V; Loizedda A; Lobina M; Zoledziewska M; Virdis F; Delogu G; Pirinu F; Marini MG; Mingoia M; Frau J; Lorefice L; Fronza M; Carmagnini D; Carta E; Orrù V; Uzzau S; Solla P; Loi F; Devoto M; Steri M; Fiorillo E; Floris M; Zarbo IR; Cocco E; Cucca F
    Front Immunol; 2021; 12():781843. PubMed ID: 34956211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy.
    Giossi R; Consonni A; Torri Clerici V; Zito A; Rigoni E; Antozzi C; Brambilla L; Crisafulli SG; Bellino A; Frangiamore R; Bonanno S; Vanoli F; Ciusani E; Corsini E; Andreetta F; Baggi F; Tramacere I; Mantegazza R; Conte A; Bergamaschi R; Confalonieri P
    Mult Scler Relat Disord; 2022 Feb; 58():103415. PubMed ID: 35216790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies.
    Drulovic J; Ivanovic J; Martinovic V; Tamas O; Veselinovic N; Cujic D; Gnjatovic M; Mesaros S; Pekmezovic T
    Mult Scler Relat Disord; 2021 Sep; 54():103150. PubMed ID: 34298478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three doses of COVID-19 vaccines in multiple sclerosis patients treated with disease-modifying therapies.
    Baba C; Ozcelik S; Kaya E; Samedzada U; Ozdogar AT; Cevik S; Dogan Y; Ozakbas S
    Mult Scler Relat Disord; 2022 Dec; 68():104119. PubMed ID: 36037755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab.
    Brill L; Rechtman A; Zveik O; Haham N; Oiknine-Djian E; Wolf DG; Levin N; Raposo C; Vaknin-Dembinsky A
    JAMA Neurol; 2021 Dec; 78(12):1510-1514. PubMed ID: 34554197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-cell depleters attenuate the humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients: A case-control study.
    Conte WL
    Mult Scler Relat Disord; 2022 Jan; 57():103413. PubMed ID: 35158480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
    Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
    Front Immunol; 2021; 12():796482. PubMed ID: 35111162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 vaccination in people with multiple sclerosis, real-life experience.
    Alroughani R; Al-Hashel J; Abokalawa F; AlMojel M; Farouk Ahmed S
    Clin Neurol Neurosurg; 2022 Sep; 220():107374. PubMed ID: 35961255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.